N NANoREG D4 13

NANoREG D2 10 DR Protocol fot size distribution analysis of primary NM particles in air powders and liquids

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d2-10-dr-protocol-fot-size-distribution-analysis-of-primary-nm-particles-in-air 

NANoREG D5.07 SOP 19 Whole blood cell assay for cytokine production

Acesse:

https://www.rivm.nl/documenten/nanoreg-d507-sop-19-whole-blood-cell-assay-for-cytokine-production 

NANoREG D1 05 DR Workshop on Preliminary feedback from stakeholders on interim output from the project

Acesse:

https://www.rivm.nl/documenten/nanoreg-d105-dr-workshop-on-preliminary-feedback-from-stakeholders-on-interim-output

NANoREG D5 08 DR Decision tree for risk assessment of MNMs

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d5-08-dr-decision-tree-for-risk-assessment-of-mnms 

RIVM FlowChart NANoREG nanospecific risk assessment strategy

NANoREG D5.07 SOP 01 SOP for Dispersion

Acesse:

https://www.rivm.nl/documenten/nanoreg-d507-sop-01-sop-for-dispersion 

NANoREG D5.03 DR In vitro screening methodology for absorption or crossing of other barriers

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d503-dr-in-vitro-screening-methodology-for-absorption-or-crossing-of-other 

SOPs available in deliverable:

• SOP 01 Protocol for organotypic cell culture modified for exposure to nanomaterials
• SOP 02 Caco-2 cell culture and differentiation
• SOP 03 Evaluation of NMs impact on Caco-2 cell barrier model